BioCardia - Warrants (26/07/2022) EBIT

As of the most recent data (March 2026), BCDAW shows a EBIT of $-5.5M. That compares with $-4M in the prior-year period — down 39.7% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCDAW's EBIT is now $-5.5M (was $-4M) — a 39.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioCardia - Warrants (26/07/2022) is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. BioCardia - Warrants (26/07/2022) is at $-5.5M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how BCDAW stacks up against individual peers as well.

Tracking BCDAW's ebit over time shows whether BioCardia - Warrants (26/07/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $-5.5M That compares with $-4M in the prior-year period — down 39.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has BioCardia - Warrants (26/07/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-5.5M) with ownership activity and broader fundamentals.